Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 813 results for "bristol myers squibb"

Is Bristol-Myers Squibb. Co. About to Fall Apart?
Motley Fool

Bristol-Myers Squibb Co (BMY) Rumored To Be Interested In Celg...

Word on the Street is that Bristol-Myers Squibb Co ( NYSE:BMY ) is interested in acquiring Celgene Corporation ( NASDAQ:CELG ). Anonymous sources have revealed that there is a possibility that Bristol-Myers may extend an offer that values Celgene ... Bidness Etc, 15 hours ago
Europe OKs First PD Inhibitor, Nivolumab Diabetes Care, 1 day ago
[x]  

251 images for bristol myers squibb

Look to the Stars, 5 days ago
Jutia Group, 3 days ago
Hollywood Industry, 1 week ago
Yahoo! News, 1 week ago
Pharmaceutical Technology, 1 week ago
Philly.com, 16 hours ago
Philly.com, 1 week ago
Benzinga.com, 1 week ago
Reuters UK, 2 weeks ago
Yahoo! News, 2 weeks ago

Bristol-Myers presents data on daclatasvir at Liver Meeting

News Editor A Phase 3 trial, ALLY-1, evaluating a 12-week regimen of the combination Bristol-Myers Squibb's (NYSE:BMY) daclatasvir and Gilead's (NASDAQ:GILD) Sovaldi (sofosbuvir) plus ribavirin (RBV) for the treatment of HCV patients with advanced ...
 Seeking Alpha5 hours ago

Bristol-Myers says hepatitis C drug combination succeeds in study

April 25 (Reuters) - Bristol-Myers Squibb Co said its experimental drug cured hepatitis C in over 90 percent of patients in combination with Gilead Sciences Inc's Sovaldi and a commonly prescribed drug, ribavirin, in a late-stage study. ...
 CNBC8 hours ago REUTERS - Bristol-Myers says hepatitis C drug combination succeeds in study  Namibia Press Agency8 hours ago
[x]  

Earnings Increase Expected for Bristol-Myers Squibb

Optimism surrounds Bristol-Myers Squibb , as it gets ready to report its first quarter results on Tuesday, April 28, 2015. Analysts are expecting the company to book a profit of 50 cents a share, up from 46 cents a year ago. Over the past three ...
 Forbes.com1 day ago

Lexicon and Bristol-Myers select new development candidate for neuropathic pain

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, and Bristol-Myers Squibb have selected a new development candidate for neuropathic pain as part of their neuroscience drug discovery and development alliance. Lexicon and Bristol-Myers ...
 Individual.com1 day ago Lexicon, Bristol-Myers select development candidate for neuropathic pain  Pharmaceutical Business Review1 week ago Lexicon Pharmaceuticals, Inc. And Bristol-Myers Squibb Select Development Candidate For Neuropathic Pain In Neuroscience Drug Discovery And Development Alliance  BioSpace1 week ago

EU regulators warn against combining hep C drugs with amiodarone

April 24 (Reuters) - European health regulators warned on Friday against using Gilead Sciences Inc's and Bristol-Myers Squibb Co's hepatitis C medicines along with amiodarone, a drug used to regulate the heartbeat of people with heart rhythm ...
 CNBC1 day ago REUTERS - EU regulators warn against combining hep C drugs with amiodarone  Namibia Press Agency1 day ago
[x]  

Bristol wins EU green light for immune system cancer drug

LONDON, April 24 (Reuters) - European regulators have recommended approval of Bristol-Myers Squibb's Opdivo, paving the way for it to become the first of a closely watched group of immune system-boosting cancer medicines to go on sale in Europe. ...
 CNBC1 day ago REUTERS - UPDATE 1-Bristol wins EU green light for immune system cancer drug  Namibia Press Agency1 day ago UPDATE 1-Bristol wins EU green light for immune system cancer drug  Reuters1 day ago REUTERS - Bristol wins EU green light for immune system cancer drug  Namibia Press Agency1 day ago
[x]  

BRIEF-EU medicines agency backs Bristol Myers Squibb's melanoma drug

(Reuters) - EU Medicines Agency: * Recommendations for April 2015 * Recommends approval of melanoma drug nivolumab from Bristol-Myers Squibb Co * Recommends approval of tasimelteon for non 24-hour sleep-wake disorder from Vanda ...
 Reuters1 day ago

SmarTrend Watching for Potential Pullback in Shares of Bristol-Myers Squibb After 1.44% Gain

(Comtex SmarTrend(R)) Bristol-Myers Squibb (NYSE:BMY) traded in a range yesterday that spanned from a low of $66.09 to a high of $67.53. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $66.26 on volume of ...
 Individual.com4 days ago Bristol-Myers Squibb Rises 2.62% on Heavy Volume: Watch For Potential Pullback  Individual.com1 week ago Buyers Accumulate Shares of Bristol-Myers Squibb, Up 2.7%  Individual.com1 week ago Look for Shares of Bristol-Myers Squibb to Potentially Pullback after Yesterday's 2.62% Rise  Individual.com1 week ago
AlertNet

Bristol's Opdivo proves effective against second type of lung cancer

(Reuters) - A large study of Bristol-Myers Squibb Co's Opdivo treatment has been halted after proving the drug is effective against a common form of lung cancer, the company said, positioning the medicine for far wider use than its already approved ...
 Reuters1 week ago UPDATE 2-Bristol's Opdivo proves effective against second type of lung cancer  CNBC1 week ago REUTERS - UPDATE 2-Bristol's Opdivo proves effective against second type of lung cancer  Namibia Press Agency1 week ago
[x]  
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - bristol myers squibb
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less